Loading organizations...
§ Private Profile · Kirkland, WA, USA
Medical device developer creating minimally invasive devices for heart failure treatment, focused on functional mitral regurgitation.
Founded in 2001 by Scott Wolf, Cardiac Dimensions is a Kirkland, Washington-based medical device developer creating minimally invasive technologies to treat patients suffering from congestive heart failure and functional mitral regurgitation. The company generates revenue through international commercial sales of its flagship Carillon Mitral Contour System, a catheter-based device utilized by interventional cardiologists to reshape the mitral valve without requiring traditional surgery. To support ongoing regulatory approvals and the completion of its United States EMPOWER clinical trial, the enterprise recently secured a $53 million strategic funding round led by Ally Bridge Group. This capital injection builds upon a previous $20 million financing round supported by institutional investors including MH Carnegie and Company, Lumira Ventures, and Arboretum Ventures. To further advance these global commercialization efforts, the organization appointed William T Abraham MD as Chief Medical Officer in 2025.
Cardiac Dimensions has raised $224.2M across 8 funding rounds.
Cardiac Dimensions has raised $224.2M in total across 8 funding rounds.
Cardiac Dimensions has raised $224.2M across 8 funding rounds. Most recently, it raised $53.0M Series E in March 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 20, 2025 | $53M Series E | Ally Bridge Group | — | Announced |
| Jan 5, 2023 | $35M Series D | Horizon 3 Healthcare | — | Announced |
| Sep 30, 2020 | $17.5M Series C | — | — | Announced |
| Apr 26, 2018 | $39M Series B | — | — | Announced |
| Mar 11, 2015 | $15.2M Venture Round | — | — | Announced |
| Oct 7, 2014 | $8.5M Venture Round | — | — | Announced |
| Apr 16, 2014 | $20M Venture Round | — | — | Announced |
| Dec 1, 2007 | $36M Series D | — | Johnson & Johnson Innovation | Announced |
Cardiac Dimensions has raised $224.2M in total across 8 funding rounds.
Cardiac Dimensions's investors include Ally Bridge Group, Horizon 3 Healthcare, Johnson & Johnson Innovation.
Cardiac Dimensions is a medical device company developing minimally invasive treatments for heart failure, particularly functional mitral regurgitation (FMR), a condition linked to heart failure that causes blood leakage through the heart's mitral valve.[1][2][5] Its flagship product, the Carillon Mitral Contour System, is a right-sided implant designed to reshape the heart, treat the underlying causes of FMR rather than just symptoms, and improve patient survival and quality of life; it has CE Mark approval and is commercially available in Europe and select regions, while remaining investigational in the US and Canada.[1][4][5] The company serves heart failure patients, especially those with advanced FMR facing limited options, and has raised $151.9M total funding, including a recent $35M round to support testing and marketing, signaling strong growth momentum backed by top-tier investors.[2][4]
Headquartered in Kirkland, Washington, with operations in Australia and Germany, Cardiac Dimensions employs about 34 people and generates around $7.2M in revenue, positioning it as a leader in innovative cardiac therapies amid rising heart failure prevalence.[1][2]
Founded in 2001, Cardiac Dimensions emerged to tackle the global heart failure crisis, where over 20% of FMR patients die within a year and 50% within five years of diagnosis.[1][3][4] The company's idea stemmed from developing novel, right-sided interventional tools to address unmet needs in FMR treatment, evolving from early research into a commercially viable product with CE Mark approval by focusing on early-stage intervention.[4][5] Key early traction included securing backing from venture investors like Lumira Capital, M.H. Carnegie & Co., Arboretum Ventures, Life Sciences Partners, and Aperture Venture Partners, enabling global expansion to Sydney and Frankfurt.[1][4] Pivotal moments include the $35M funding round for the Carillon system and recent leadership additions, such as Chief Medical Officer William T. Abraham, MD, in 2025, bolstering its clinical push.[2][3]
Cardiac Dimensions rides the wave of advancing transcatheter therapies for structural heart disease, addressing a massive unmet need as heart failure affects millions globally with poor prognosis and high costs.[1][2][5] Timing is ideal amid trends like rising FMR prevalence, growth in markets such as transcatheter mitral valve replacement (TMVR) and MRI-safe cardiac devices (projected 9.6% CAGR), and a shift toward minimally invasive, symptom-relieving implants over open surgery.[3][5] Favorable market forces include aging populations, investor interest in medtech (evidenced by its funding), and regulatory progress like CE Mark, enabling European adoption while US trials pave the way for FDA approval.[1][2][4] It influences the ecosystem by pioneering right-sided FMR treatments, potentially reshaping guidelines and spurring competition in heart failure innovation.
Cardiac Dimensions is poised for expansion with US pivotal trials, potential FDA approval, and broader commercialization of the Carillon system, leveraging its $35M infusion and expert leadership.[2][3] Trends like AI-driven diagnostics, personalized cardiac care, and TMVR growth will shape its path, amplifying impact on FMR survivability.[3][5] Its influence may evolve from niche innovator to standard-of-care leader, restoring hope for heart failure patients as it scales globally—fulfilling its mission to treat earlier and live longer.[1]